The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia

Elderly chronic lymphocytic leukaemia (CLL) patients treated outside of trials have notably greater toxicity with the Bruton’s tyrosine kinase inhibitor ibrutinib compared to younger patients. It is not known whether the same holds true for the B-cell lymphoma 2 inhibitor venetoclax. We provide a co...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Haematol
Autors principals: Eyre, Toby A., Roeker, Lindsey E., Fox, Christopher P., Gohill, Satyen H., Walewska, Renata, Walter, Harriet S., Forconi, Francesco, Broom, Angus, Arumainathan, Arvind, Brander, Danielle M., Allan, John N., Schuster, Stephen J., Hill, Brian T., Lansigan, Frederick, Cheson, Bruce D., Lamanna, Nicole, Coombs, Catherine C., Barr, Paul M., Skarbnik, Alan P., Shadman, Mazyar, Ujjani, Chaitra S., Pearson, Laurie, Pagel, John M., Jacobs, Ryan, Mato, Anthony R.
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7528953/
https://ncbi.nlm.nih.gov/pubmed/31682002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16271
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars